Philadelphia Chromosome Positive Cml Therapeutics
1. Gleevec patent expiration
Treatment: A method for treating a tumor disease; Gleevec is also indicated for the treatment of patients with kit (cd117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (gist)
GLEEVEC IPR and PTAB Proceedings
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE43932 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul, 2018
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US5521184 (Pediatric) | NOVARTIS | Pyrimidine derivatives and processes for the preparation thereof |
Jul, 2015
(10 years ago) | |
| US6894051 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
May, 2019
(6 years ago) | |
| US5521184 | NOVARTIS | Pyrimidine derivatives and processes for the preparation thereof |
Jan, 2015
(11 years ago) | |
| USRE43932 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jan, 2019
(6 years ago) | |
| US6958335 | NOVARTIS | Treatment of gastrointestinal stromal tumors |
Dec, 2021
(4 years ago) | |
| US7544799 | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jan, 2019
(6 years ago) | |
|
US7544799 (Pediatric) | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul, 2019
(6 years ago) | |
|
USRE43932 (Pediatric) | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Jul, 2019
(6 years ago) | |
|
US6894051 (Pediatric) | NOVARTIS | Crystal modification of a N-phenyl-2-pyrimidineamine derivative, processes for its manufacture and its use |
Nov, 2019
(6 years ago) | |
|
US6958335 (Pediatric) | NOVARTIS | Treatment of gastrointestinal stromal tumors |
Jun, 2022
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-583) | Dec 19, 2011 |
| Orphan Drug Exclusivity(ODE) | Jan 25, 2020 |
| New Indication(I-666) | Jan 25, 2016 |
| Orphan Drug Exclusivity(ODE-40) | Jan 25, 2020 |
Drugs and Companies using IMATINIB MESYLATE ingredient
Market Authorisation Date: 10 May, 2001
Dosage: CAPSULE; TABLET
How can I launch a generic of GLEEVEC before it's drug patent expiration?
More Information on Dosage
GLEEVEC family patents
2. Scemblix patent expiration
Treatment: Treatment of philadelphia chromosome positive chronic myeloid leukemia (ph+cml)
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8829195 | NOVARTIS | Compounds and compositions for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 |
Oct, 2035
(9 years from now) | |
| US11407735 | NOVARTIS | Crystalline forms of N-[4-(Chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
May, 2040
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US12252479 | NOVARTIS | Crystalline forms OF N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
May, 2040
(14 years from now) | |
| US12252478 | NOVARTIS | Crystalline forms of N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3R)-3-hydroxypyrrolidin-1-yl]-5-(1H-pyrazol-5-yl)pyridine-3-carboxamide |
May, 2040
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 29, 2026 |
| New Indication(I-953) | Oct 29, 2027 |
| New Indication(I-954) | Oct 29, 2027 |
| ODE*(ODE*) | Oct 29, 2028 |
| Orphan Drug Exclusivity(ODE-381) | Oct 29, 2028 |
| Orphan Drug Exclusivity(ODE-382) | Oct 29, 2028 |
| Orphan Drug Exclusivity(ODE-499) | Oct 29, 2031 |
| Orphan Drug Exclusivity(ODE-500) | Oct 29, 2031 |
Drugs and Companies using ASCIMINIB HYDROCHLORIDE ingredient
NCE-1 date: 29 October, 2025
Market Authorisation Date: 29 October, 2021
Dosage: TABLET
More Information on Dosage
SCEMBLIX family patents